| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.047 | 0.4 |
| mRNA | itraconazole | CTRPv2 | pan-cancer | AAC | 0.029 | 0.4 |
| mRNA | QL-XII-47 | GDSC1000 | pan-cancer | AAC | 0.025 | 0.4 |
| mRNA | BMS-195614 | CTRPv2 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.028 | 0.4 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.026 | 0.4 |
| mRNA | bafilomycin A1 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.4 |
| mRNA | VX-11e | GDSC1000 | pan-cancer | AAC | -0.025 | 0.4 |
| mRNA | spautin-1 | CTRPv2 | pan-cancer | AAC | 0.028 | 0.4 |
| mRNA | BRD-A86708339 | CTRPv2 | pan-cancer | AAC | 0.038 | 0.4 |